The average one-year price target for Harvard Bioscience (NasdaqCM:HBIO) has been revised to $6.12 / share. This is an increase of 200.00% from the prior estimate of $2.04 dated February 21, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $6.06 to a high of $6.30 / share. The average price target represents an increase of 20.71% from the latest reported closing price of $5.07 / share.
What is the Fund Sentiment?
There are 71 funds or institutions reporting positions in Harvard Bioscience. This is an decrease of 59 owner(s) or 45.38% in the last quarter. Average portfolio weight of all funds dedicated to HBIO is 0.07%, an increase of 215.25%. Total shares owned by institutions increased in the last three months by 17.87% to 21,739K shares. 
The put/call ratio of HBIO is 0.07, indicating a bullish outlook.
What are Other Shareholders Doing?
AMH Equity holds 4,048K shares representing 91.61% ownership of the company. In its prior filing, the firm reported owning 3,509K shares , representing an increase of 13.31%. The firm increased its portfolio allocation in HBIO by 8.00% over the last quarter.
Weber Capital Management holds 3,200K shares representing 72.44% ownership of the company.
Acadian Asset Management holds 1,773K shares representing 40.12% ownership of the company. In its prior filing, the firm reported owning 1,070K shares , representing an increase of 39.66%. The firm increased its portfolio allocation in HBIO by 138.51% over the last quarter.
Meros Investment Management holds 1,218K shares representing 27.56% ownership of the company. In its prior filing, the firm reported owning 918K shares , representing an increase of 24.59%. The firm increased its portfolio allocation in HBIO by 87.84% over the last quarter.
Corsair Capital Management holds 1,109K shares representing 25.09% ownership of the company. In its prior filing, the firm reported owning 100K shares , representing an increase of 90.98%. The firm increased its portfolio allocation in HBIO by 1,480.33% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
